Saving changes...

Done

Error

Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions

Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions

Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions

Veterinary Cancer Society -- Dr. John Paul Shen
Veterinary Cancer Society -- Dr. John Paul Shen
on behalf of Missouri Veterinary Medical Association

$FREE $ FREE $ FREE

$ FREE $ FREE $ FREE
$ 25.00 $ 25.00 $ 25.00
Normal Price: FREE $25.00

Review:

Launch date: 26 Dec 2018
Expiry Date:

Last updated: 27 Feb 2019

Reference: 193137

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

The current treatment of solid tumors is limited by both a lack of targeted therapies, and a lack of diagnostic tests to help oncologists identify the best chemotherapy for an individual patient. To address these needs we are utilizing high-throughput functional genomic screens to identify specific, targetable vulnerabilities in cancer cell lines and primary tumors. This strategy has been made possible by recent advances in genome editing technology now allowing for the knockout of pairs of genes in high-throughput, enabling thousands of genetic interactions to be tested simultaneously. Recognizing that cancer is a tremendously heterogeneous disease, these vulnerability screens are conducted in extensively molecularly profiled models, so that once the specific vulnerabilities of each tumor are identified, systems biology and machine-learning techniques can be used to link these vulnerabilities to molecular features, identifying biomarkers to predict which patients will respond to that specific therapy.

Objectives

Learning Objectives
• What is the CRISPR-Cas9 system and where did it come from?
• What are the key technologies that allow for high-throughput, pooled screens with CRISPR?
• How can the mapping of genetic interactions impact the future of oncology?
Veterinary Cancer Society -- Dr. John Paul Shen

Author Information Play Video Bio

Veterinary Cancer Society -- Dr. John Paul Shen
on behalf of Missouri Veterinary Medical Association

Dr. John Paul Shen
Assistant Professor
Department of Gastrointestinal Medical Oncology
University of Texas MD Anderson Cancer Center
Dr. Shen, a Physician-Scientist and Medical Oncologist at the University of California-San Diego will review his work, recently published in Nature Methods, regarding ground breaking advances in the application of CRISPR/Cas9 technology for the identification of novel cancer treatment approaches (and possibly prevention).

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Missouri Veterinary Medical Association
  • 1.00 Hours -
    Exam Attempts: 3
    -
    Exam Pass Rate: 60

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error